Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Tamoxifen × 30 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 18 Carcinoma, Intraductal, Noninfiltrating 4 Breast Carcinoma In Situ 3 Prostatic Neoplasms 1 Neoplasms 1 Hypogonadism 1 Hot Flashes 1 Carcinoma, Ductal 1 Breast Neoplasms, Male 1 Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Magnetic Resonance Spectroscopy 24 apalutamide 22 Specimen Handling 19 Abiraterone Acetate 18 enzalutamide 17 Pluvicto 16 Prednisone 15 Radiosurgery 12 Androgen Antagonists 12 Docetaxel 10 darolutamide 9 Leuprolide 8 Biopsy 7 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 7 relugolix 6 Triptorelin Pamoate 6 Surveys and Questionnaires 6 Radiotherapy 6 Nivolumab 6 cabazitaxel 5 bicalutamide 5 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5 abiraterone 5 Standard of Care 5 Radiation 5 Goserelin 5 Educational Status 5 Carboplatin 5 olaparib 4 gallium 68 PSMA-11 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07535905 2026-04-17

REVIVE

University Health Network, Toronto

Phase 2 Not yet recruiting

Hypogonadism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡